ArticleTranslational cancer research2026
UBA6 serves as a prognostic biomarker and promotes tumor progression in pancreatic ductal adenocarcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The limited availability of reliable biomarkers for prognostic risk stratification in pancreatic ductal adenocarcinoma (PDAC) constrains long-term patient survival. There is a pressing need to identify molecular indicators possessing high sensitivity and specificity. This study aimed to evaluate the prognostic significance of UBA6 and its association with tumor progression in PDAC. Methods: Prognostic candidate genes were identified through univariate Cox regression analysis and subsequent Venn diagram intersection. Their expression profiles were contrasted across PDAC specimens and matched adjacent non-tumorous tissues in multiple independent cohorts. Cellular expression patterns were resolved using single-cell RNA sequencing data. The predictive accuracy for survival was evaluated via Kaplan-Meier (K-M) survival analysis, receiver operating characteristic (ROC) curves, and calibration plots. Associations between gene expression and immune cell infiltration levels were estimated using Pearson correlation. Functional pathway enrichment was investigated with Gene Set Enrichment Analysis (GSEA). The impact on malignant phenotypes was assessed through Results: Ubiquitin-like modifier activating enzyme 6 (UBA6) was robustly identified as a prognostic marker through Cox regression and intersection analysis. Its expression, both at the transcript and protein levels, was significantly upregulated in tumor tissues and associated with poorer patient outcomes. At the single‑cell resolution, UBA6 was found to be predominantly expressed in malignant ductal cells. Elevated UBA6 expression also correlated with reduced infiltration of CD8 Conclusions: This study identifies UBA6 as a robust and independent predictor of overall survival (OS) in PDAC, validates its prognostic utility, and delineates its tumor-promoting role in disease progression. These findings enhance the understanding of PDAC pathogenesis and could inform the development of improved clinical management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.